Long-term sertraline treatment and peripheral biochemical markers in female depressed patients

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 27, Issue 5, 2003, Pages 759-765

  Pivac, Nela ^a   Mück Šeler, Dorotea ^a   Šagud, Marina ^b   Jakovljević, Miro ^b   Mustapić, Maja ^a   Mihaljević Peleš, Alma ^b  

^a RUDER BO KOVI INSTITUTE   (Croatia)

^b KBC Zagreb   (Croatia)

Author keywords

Blood platelets; Major depression; Monoamine oxidase; Remission; Response and nonresponse; Serotonin; Sertraline

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); BIOLOGICAL MARKER; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; ANOREXIA; ARTICLE; CELL LEVEL; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPRESSION; DIARRHEA; DRUG MECHANISM; ENZYME ACTIVITY; FEMALE; FOLLOW UP; HEADACHE; HUMAN; LONG TERM CARE; NAUSEA; PREDICTION; PROGNOSIS; REMISSION; SPECTROFLUOROMETRY; THROMBOCYTE; TREATMENT OUTCOME;

EID: 0043133764     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(03)00105-2     Document Type: Article

References (56)

1. Alvarez J.C., Gluck N., Arnulf I., Quintin P., Leoboyer M., Pecquery R., Launay J.M., Perez-Diaz F., Spreux-Varoquaux O. Decreased platelet serotonin transporter sites and increased platelet inositol triphosphate levels in patients with unipolar depression: effects of clomipramine and fluoxetine. Clin. Pharmacol. Ther. 66:1999;617-624.
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders. 4th ed. 1994;American Psychiatric Press, Washington, DC.
3. Anderson I.M. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J. Affect. Disord. 58:2000;19-36.
4. 2 receptor binding properties and their regulation by endogenous serotonin. Life Sci. 52:1993;313-321.
5. Artigas F., Perez V., Alvarez E. Pretreatment platelet 5-HT concentration predicts the short-term response to paroxetine in major depression. Reply. Biol. Psychiatry. 47:2000;846-847.
6. Axelson D.A., Perel J.M., Birmaher B., Rudolph G.R., Nuss S., Bridge J., Brent D.A. Sertraline pharmacokinetics and dynamics in adolescents. J. Am. Acad. Child Adolesc. Psych. 41:2002;1037-1044.
7. Butler J., Leonard B.E. The platelet serotonergic system in depression and following sertraline. Int. Clin. Psychopharmacol. 3:1988;343-347.
8. Camacho A., Dimsdale J.E. Platelets and psychiatry: lessons learned from old and new studies. Psychosom. Med. 62:2000;326-336.
9. Figueras G., Perez V., San Martino O., Alvarez E., Artigas F. Pretreatment platelet 5-HT concentration predicts the short-term response to paroxetine in major depression. Biol. Psychiatry. 46:1999;518-524.
10. Georgotas A., McCue R.E., Friedman E., Cooper T. Prediction of response to nortriptyline and phenelzine by platelet MAO activity. Am. J. Psychiatry. 144:1987;338-340.
11. Goodnick P.J., Kumar A. Pretreatment platelet 5-HT concentration predicts the short-term response to paroxetine in major depression. Letter to the editor. Biol. Psychiatry. 47:2000;846.
12. Goodnick P.J., Henry J., Kumar A. Neurochemistry and paroxetine response in major depression. Biol. Psychiatry. 37:1995;417-419.
13. Goodnick P.J., Kumar A., Henry J.H., Goldberg R.B. Sertraline in coexisting major depression and diabetes mellitus. Psychopharmacol. Bull. 33:1997;261-264.
14. Guicheney P., Leger D., Barrat J., Trevoux R., De Lignieres B., Roques P., Garnier J.P., Boyers P., Grenier J., Dreux C., Meyer P. Platelet serotonin content and plasma tryptophan in peri- and postmenopausal women: variations with plasma oestrogen levels and depressive symptoms. Eur. J. Clin. Invest. 18:1988;297-304.
15. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised Version. 1976;U.S. Department of Health, Education and Welfare, Bethesda, MD.
16. Jakovljević M., Mück-Šeler D., Pivac N., Ljubićič E., Bujas M., Dodig G. Seasonal influence on platelet 5-HT levels in patients with recurrent major depression and schizophrenia. Biol. Psychiatry. 41:1997;1028-1034.
17. James J., Padayatti P.S., Paul T., Paulose C.S. Platelet monoamine changes in diabetic patients and streptozotocin-induced diabetic rats. Curr. Sci. 72:1997;137-139.
18. Javors M.A., Houston J.P., Tekell J.L., Brannan S.K., Frazer A. Reduction of platelet serotonin content in depressed patients treated with either paroxetine or desipramine. Int. J. Neuropsychopharmacol. 3:2000;229-235.
19. Koran L.M., Gelenborg A.J., Kornstein S.G., Howland R.H., Friedman R.A., Debattista C., Klein D., Kocsis J.H., Schatzberg A.F., Thase M.E., Rush A.J., Hirschfeld R.M.A., LaVinge L.M., Keller M.B. Sertraline versus imipramine to prevent relapse in chronic depression. J. Affect. Disord. 65:2001;27-36.
20. Krajl M. A rapid microfluorimetric determination of monoamine oxidase. Biochem. Pharmacol. 14:1965;1683-1685.
21. Kutcher S., Leblanc J., Maclaren C., Hadrava V. A randomized trial of a specific adherence enhancement program in sertraline-treated adults with major depressive disorder in a primary care setting. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 26:2002;591-596.
22. Leibenluft E., Fiero P.L., David R. Effects of menstrual cycle on dependent variables in mood disorder research. Arch. Gen. Psychiatry. 51:1994;761-781.
23. Lestra C., D'Amato T., Ghaemmaghami C., Perret-Liaudet A., Broyer M., Renaud B., Dalery J., Chamba G. Biological parameters in major depression: effects of paroxetine, viloxazine, moclobemide and electroconvulsive therapy. Biol. Psychiatry. 44:1998;274-280.
24. Licht R.W., Qvitzau S. Treatment strategies in patients with major depression not responding to first-line sertraline treatment. A randomized study of extended duration of treatment, dose increase or mianserin augmentation. Psychopharmacology. 161:2002;143-151.
25. Lowry O.H., Rosenbrough N.S., Farr A.C., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
26. Lucki I. The spectrum of behaviors influenced by serotonin. Biol. Psychiatry. 44:1998;151-162.
27. MacQuin G., Born L., Steiner M. The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders. CNS Drug Rev. 7:2001;1-24.
28. Maes M., Meltzer H.Y. The serotonin hypothesis of major depression. Bloom F.E., Kupfer D.J. Psychopharmacology: The Fourth Generation of Progress. 1995;933-944 Raven Press, New York.
29. McIntyre R., Kennedy S., Bagby M., Bakish D. Assessing full remission. J. Psychiatry Neurosci. 27:2002;235-239.
30. Montgomery S., Asperg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry. 134:1979;382-389.
31. Mück-Šeler D., Jakovljević M., Deanović Ž. Effect of antidepressant treatment on platelet 5-HT content and relation to therapeutic outcome in unipolar depressive patients. J. Affect. Disord. 23:1991;157-164.
32. Mück-Šeler D., Jakovljević M., Pivac N. Platelet 5-HT concentrations and suicidal behavior in recurrent major depression. J. Affect. Disord. 39:1996;73-80.
33. Mück-Šeler D., Bujas M., Ljubić-Thiebal V., Jakovljević M. Effect of age on platelet 5-HT concentrations in healthy controls, depressed and schizophrenic patients. Neuropsychobiology. 34:1996;201-203.
34. Mück-Šeler D., Pivac N., Jakovljević M. Sex differences, season of birth and platelet 5-HT levels in schizophrenic patients. J. Neural Transm. 106:1999;337-347.
35. Mück-Šeler D., Pivac N., Jakovljević M., Šagud M., Mihaljević-Peleš A. The effects of paroxetine and tianeptine on peripheral biochemical markers in major depression. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 26:2002;1235-1243.
36. Oreland L., Shaskan E.G. Monoamine oxidase activity as a biological marker. Trends Pharmacol. Sci. 4:1983;339-341.
37. Oreland L., Damberg M., Hallman J., Garpenstrand H. Smoking only explains part of the associations between platelet monoamine oxidase activity and personality. J. Neural Transm. Gen. Sect. 109:2002;963-975.
38. Ortiz J., Mariscot C., Alvarez E., Artigas F. Effects of the antidepressant drug tianeptine on plasma and platelet serotonin in depressed patients and healthy controls. J. Affect. Disord. 29:1993;227-234.
39. Phillips O.M., Wood K.M., Williams D.C. Kinetics of the interaction of sertraline with the human platelet membrane 5-hydroxytryptamine carrier. Eur. J. Pharmacol. 146:1988;299-306.
40. Pivac N., Mück-Šeler D., Jakovljević M., Brzović Z. Hypothalamic-pituitary-adrenal axis function and platelet serotonin concentrations in depressed patients. Psychiatry Res. 73:1997;123-132.
41. Pivac N., Mück-Šeler D., Barišić I., Jakovljević M., Puretić Z. Platelet serotonin concentration in dialysis patients with somatic symptoms of depression. Life Sci. 68:2001;2423-2433.
42. Roy A., Linnoila M. Suicidal behavior, impulsiveness and serotonin. Acta Psychiatr. Scand. 78:1988;529-535.
43. Šagud M., Pivac N., Mück-Šeler D., Jakovljević M., Mihaljević-Peleš A., Koršić M. Effects of sertraline treatment on plasma cortisol, prolactin and thyroid hormones in female depressed patients. Neuropsychobiology. 45:2002;139-143.
44. 3H-paroxetine binding before and after sertraline. J. Am. Acad. Child Adolesc. Psych. 37:1998;777-784.
45. Sanchez C., Hyttel J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell. Mol. Neurobiol. 19:1999;467-489.
46. Sarrias M.J., Artigas F., Martinez E., Gelpi E., Alvarez E., Udina C., Casas M. Decreased plasma serotonin in melancholic patients: a study with clomipramine. Biol. Psychiatry. 22:1987;1429-1438.
47. Serretti A., Zanardi R., Cusin C., Rossini D., Lorenzi C., Smeraldi E. Tryptophan hydroxylase gene associated with paroxetine antidepressant activity. Eur. Neuropsychopharmacol. 11:2001;375-380.
48. Stahl S.M. Platelets as pharmacological models for the receptors and biochemistry of monoaminergic neurons. Longenecker G.L. Platelets: Physiology and Pharmacology. 1985;307-340 Academic Press, New York.
49. Stahl S.M. Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J. Affect. Disord. 51:1998;215-235.
50. Stahl S.M. Why settle for silver, when you can go for gold? Response vs. recovery as the goal of antidepressant therapy. J. Clin. Psychiatry. 60:1999;213-214.
51. Stahl S.M. So many choices, so little time. Int. J. Neuropsychopharmacol. 5(Suppl. 1):2002;225.
52. Stain-Malmgren R., El Khoury A., Aberg-Wistedt A., Tham A. Serotonergic function in major depression and effect of sertraline and paroxetine treatment. Int. Clin. Psychopharmacol. 16:2001;93-101.
53. 3H)-IMI platelet binding and clinical response in major depression? Neuropsychopharmacology. 14:1996;47-53.
54. 3H] paroxetine binding related to impulsive suicide attempts and borderline personality disorder. Biol. Psychiatry. 43:1998;740-746.
55. Warrington S.J. Clinical implications of the pharmacology of sertraline. Int. Clin. Psychopharmacol. 6(Suppl. 2):1991;11-21.
56. Whitfield J.B., Pang D., Bucholz K.K., Madden P.A., Heath A.C., Statham D.J., Martin N.G. Monoamine oxidase: associations with alcohol dependence, smoking and other measures of psychopathology. Psychol. Med. 30:2000;443-454.